Izindaba

Esimweni somtholampilo esiphambili, isiguli esineminyaka engu-21 ubudala sanqoba ngempumelelo izinselele ze-thalassemia ngokusebenzisa ukwelashwa kwezakhi zofuzo okusekelwe ku-CRISPR okuthuthukisiwe. Le ndlela entsha iphawula ingqophamlando ebalulekile ekwelapheni izifo ezinkulu zegazi ezifana nesifo se-sickle cell (SCD) kanye ne-thalassemia.

Engqungqutheleni ezayo ye-ASH 2024, ithimba lezokwelapha leSibhedlela iLu Daopei lizokwethula imiphumela yocwaningo engu-13 ephawulekayo, liqokomisa intuthuko kwezokwelapha ngegazi kanye nekhono lokwelashwa nge-CAR-T, liphinde liqinisekise ukuzibophezela kwalo ekuthuthukiseni imiphumela yeziguli.

Ngemva kokulwa ne-lymphoma iminyaka emithathu, owesifazane oneminyaka engu-61 ubudala uthole ukuphulukiswa okuphelele ngokwelashwa okusha kwe-CAR-T e-BIOOCUS, okubonisa amandla okushintsha impilo okwelashwa komdlavuza okuthuthukisiwe.

Intuthuko yakamuva kwezobuchwepheshe be-CRISPR/Cas ishintsha isimo sokuhlela izakhi zofuzo ocwaningweni lwezokwelapha. Lesi sihloko sihlola ukusetshenziswa kwaso, siqokomisa amandla abalulekile okwelapha izifo zofuzo, umdlavuza, kanye nezifo ezithathelwanayo.

Icala elimangalisayo e-BIOOCUS libonisa umthelela wokuguqula ukwelashwa kwe-CD7 CAR-T kumfana oneminyaka engu-15 ubudala one-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yabuya, okuholela ekuphumuleni okuphelele kanye nokufakelwa kwesibili okuphumelelayo.

I-Bioocus ijabule kakhulu ukujoyina i-8th Immuno-Gene and Cell Therapy Congress (IGC 2024)! Silangazelela ukubambisana nochwepheshe bomhlaba wonke nokuhlola amamodeli ebhizinisi amasha ahambisana nobuchwepheshe besimanje bezakhi zofuzo kanye nokwelashwa kwamaseli. Sisonke, ake sakhe ikusasa le-immunotherapy.

Lesi sihloko sezindaba siqokomisa ucwaningo lwakamuva mayelana nokuphatha ubuthi bokwelashwa kwamaseli e-CAR-T kuma-B-cell lymphomas. Ucwaningo lugcizelela amasu okusingatha imiphumela emibi evamile njenge-cytokine release syndrome (CRS) kanye ne-neurotoxicity (ICANS), okuqinisekisa ukusetshenziswa okuphephile kwalokhu kwelashwa okusha.

Ucwaningo lwakamuva luqokomisa ukusebenza kahle nokuphepha kokwelashwa kwamaseli e-CD7 CAR-T ekwelapheni i-B-cell acute lymphoblastic leukemia (B-ALL) ephinde yabuya noma engaphikisi kanye ne-T-cell lymphoblastic lymphoma (T-LBL). Lolu cwaningo lwenziwa yi-BIOOCUS ngokubambisana ne-Lu Daopei Hospital, lubonisa imiphumela ethembisayo ezigulini, lunikeza enye indlela enamandla esikhundleni se-chemotherapy evamile.

Ucwaningo, olushicilelwe ku- Ijenali ye-Clinical Oncology, kubonisa amazinga aphezulu okukhululwa ezigulini ezazisebenzise izindlela zokwelapha zendabuko, okubonisa intuthuko ethembisayo ekwelashweni komdlavuza.

Ucwaningo lwamuva nje luqokomisa ukusebenza kahle kokwelashwa kwe-CD7 CAR-T okulandelwa ukufakelwa kwesibili kwe-allogeneic hematopoietic stem cell (HSCT) ezigulini ezine-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yatholakala kanye ne-lymphoblastic lymphoma (LBL), okubonisa amandla amakhulu ekufezeni ukukhululwa okuphelele kwesifo esisele (MRD)-negative.

Ucwaningo oluqavile lubonisa impumelelo yesikhathi eside yokwelashwa kwe-CD19 CAR T-cell ekwelapheni iziguli ezine-relapse/refractory acute lymphoblastic leukemia (ALL) ngemuva kokufakelwa kwe-allogeneic hematopoietic stem cell, okunikeza ithemba elisha ku-hematology.

I-Bioocus ihamba phambili ekuthuthukiseni ukwelashwa kwe-CAR-T kwesizukulwane esilandelayo. Incwadi yakamuva kaDkt. Chunrong Tong kanye nethimba lakhe eSibhedlela iLu Daopei iqokomisa intuthuko ebalulekile kanye nezinselele ekusetshenzisweni kokwelashwa kwe-CD19 CAR-T kwesizukulwane sesibili ezigulini zezingane, okubonisa ukuzibophezela kwe-Bioocus ekwelashweni komdlavuza okusha.